XSHE
002940
Market cap750mUSD
Jul 10, Last price
27.11CNY
1D
4.43%
1Q
-12.66%
IPO
55.99%
Name
Zhejiang Anglikang Pharmaceutical Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zhejiang AngLiKang Pharmaceutical CO.,LTD. is a company primarily focused on the manufacturing and distribution of various pharmaceutical goods. Their operations span the production and sale of active pharmaceutical ingredients (APIs), finished drug formulations, and empty capsules for medical use. The company's existing product line encompasses treatments for a variety of conditions, including anti-infective agents, antihypertensives for blood pressure management, medications for digestive system health, and respiratory preparations. Beyond its current offerings, AngLiKang is also deeply involved in drug research and development. Their R&D efforts are concentrated on creating new therapies, with a particular emphasis on oral cephalosporin antibiotics, as well as treatments for cardiovascular, renal (kidney), and central nervous system diseases. The company was established in 2001 and maintains its headquarters in Shengzhou, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||